Bersudsky V, Blum-Hareuveni T, Rehany U, Rumelt S
Department of Ophthalmology, Western Galilee-Nahariya Medical Center, Nahariya, Israel.
Ophthalmology. 2001 Mar;108(3):461-9. doi: 10.1016/s0161-6420(00)00544-3.
To evaluate the primary indications for corneal transplantation in patients with repeated keratoplasties, graft survival, the causes and risk factors for failure.
Tertiary referral care center.
Retrospective, noncomparative case series.
Charts of all patients who underwent repeated corneal transplantation between 1985 and 1998 were reviewed. Eighty patients underwent repeated corneal transplantation, of which six underwent repeated corneal transplantation in both eyes, totaling 86 eyes. A total of 208 keratoplasties were performed in this group; 86 primary and 122 repeated keratoplasties. The most common primary indications for corneal transplantation were vascularized corneal scar in 31 of the 86 eyes (36%), followed by pseudophakic and aphakic bullous keratopathy (PBK, ABK). Of the repeated transplants, 55 eyes (64%) had one repeated graft, 27 eyes (31.4%) had two repeated grafts, three (3.5%) had three repeated grafts, and one (1.2%) had four repeated transplants.
Final visual outcome and clarity of corneal graft.
At the end of the follow-up period, 44 of the 86 eyes (51%) had clear grafts, but only 39.5% had good visual outcome. The mean survival periods of the repeated transplants decreased gradually with the number of regrafting procedures, from 14.3 to 8.7 months. The mean survival period was longer for patients with ABK, PBK, and secondary glaucoma, and shorter for patients who experienced graft ulcer or surface disorders. Graft failure was unrelated to graft size, but was associated with vascularization (P = 0.025), additional surgical procedures (P < 0.0001), and postoperative complications (P < 0.0001). There was a constant tendency for decrease in visual acuity with time. Final visual acuity was 20/20 to 20/40 in 13 of the 86 eyes (15%), 20/80 to 20/200 in 23 eyes (27%), and less than 20/200 in 50 eyes (58%). The most common complication was immune rejection, which occurred in 65 of the 208 transplants (31%), followed by secondary glaucoma in 48 eyes (23%) and cataract in 19 eyes (9%). Graft survival decreased remarkably after the third and forth regrafts, to 25% and 0%, respectively, compared with the first and second regrafts, 37% and 43%, respectively.
"High-risk" preoperative conditions, postoperative complications, and the need for additional surgical interventions may decrease graft survival. Close follow-up, extended use of antiinflammatory, antiviral, and immunosuppressive drugs, and avoiding additional surgical interventions as much as possible may decrease graft failure and the need for repeated keratoplasties.
评估再次角膜移植患者的角膜移植主要适应证、移植物存活率、失败原因及危险因素。
三级转诊护理中心。
回顾性、非对照病例系列研究。
回顾1985年至1998年间所有接受再次角膜移植患者的病历。80例患者接受了再次角膜移植,其中6例患者双眼均接受了再次角膜移植,共计86只眼。该组共进行了208次角膜移植手术;86次初次移植和122次再次移植。角膜移植最常见的主要适应证为86只眼中31只眼(36%)的血管化角膜瘢痕,其次为人工晶状体眼和无晶状体眼大泡性角膜病变(PBK,ABK)。在再次移植中,55只眼(64%)进行了1次再次移植,27只眼(31.4%)进行了2次再次移植,3只眼(3.5%)进行了3次再次移植,1只眼(1.2%)进行了4次再次移植。
最终视力结果和角膜移植物清晰度。
随访期末,86只眼中44只眼(51%)的移植物清晰,但只有39.5%的患者视力良好。再次移植的平均存活期随着再次移植次数的增加而逐渐缩短,从14.3个月降至8.7个月。ABK、PBK和继发性青光眼患者的平均存活期较长,而发生移植物溃疡或表面病变的患者平均存活期较短。移植物失败与移植物大小无关,但与血管化(P = 0.025)、额外的手术操作(P < 0.0001)和术后并发症(P < 0.0001)有关。视力随时间有持续下降的趋势。86只眼中13只眼(15%)的最终视力为20/20至20/40,23只眼(27%)为20/80至20/200,50只眼(58%)低于20/200。最常见的并发症是免疫排斥反应,在208次移植中有65次(31%)发生,其次是48只眼(23%)发生继发性青光眼和19只眼(9%)发生白内障。与第一次和第二次再次移植分别为37%和43%相比,第三次和第四次再次移植后移植物存活率显著下降,分别降至25%和0%。
“高危”的术前情况、术后并发症以及额外手术干预的需求可能会降低移植物存活率。密切随访、延长抗炎、抗病毒和免疫抑制药物的使用,并尽可能避免额外手术干预,可能会降低移植物失败率和再次角膜移植的需求。